|
Acomplia know as well as rimonabant is an anti-obesity drug. It was approved for marketing in the European
Union in June 2006. Acomplia is not yet approved for use in the United States, where it is known as Zimulti.
Current medication is the first in a new class of therapeutic agents called Cannabinoid-1 Receptor Blockers (CB1)
destined to treat obesity and related conditions.
Acomplia is used complementary to diet and exercise to treat obese or overweight patients who suffer from
Type 2 diabetes and abnormal levels of fat in the blood. Sometimes current medication can prevent the risk of
cardiovascular disease.
Recommendat
|
